Goldman downgrades Watson Pharma

Goldman Sachs dealt a blow to Watson Pharmaceuticals today, downgrading the generics maker to "sell" and recommending that investors short the stock. A Goldman analyst cited the potential for lower sales of the iron-deficiency drug Ferrlecit and the company's intent to expand overseas. Report

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.